<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>/<z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) is an increasingly recognized treatment complication in patients treated with radiotherapy or chemotherapy for previous <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> or <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Distinct clinical entities have been described according to the primary treatment, corresponding to defined genetic lesions </plain></SENT>
<SENT sid="2" pm="."><plain>Chromosome 7 and/or 5 losses or deletions are typical of <z:chebi fb="0" ids="22333">alkylating agent</z:chebi>-induced <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, while development of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with balanced translocations involving chromosome bands 11q23 and 21q22 has been related to previous therapy with drugs targeting DNA-topoisomerase II </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, <z:chebi fb="0" ids="35221">antimetabolites</z:chebi>, and in particular the <z:chebi fb="1" ids="35705">immunosuppressant</z:chebi> <z:chebi fb="2" ids="2948">azathioprine</z:chebi>, have been shown to induce defective DNA-mismatch repair </plain></SENT>
<SENT sid="4" pm="."><plain>This could promote survival of misrepaired cells giving rise to the leukemic clone </plain></SENT>
<SENT sid="5" pm="."><plain>Individual predisposing factors, including polymorphisms in detoxification and DNA repair enzymes have been identified </plain></SENT>
<SENT sid="6" pm="."><plain>Their combination may significantly increase the risk of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Among patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, long-term survivors of Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> are exposed to an increased risk of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy </plain></SENT>
<SENT sid="8" pm="."><plain>Patients with Hodgkin's and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> are at highest risk when total body irradiation followed by autologous stem cell transplantation is used as rescue or consolidation therapy </plain></SENT>
<SENT sid="9" pm="."><plain>The addition of granulocyte-colony-stimulating factor and radiotherapy plays a significant role in t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> following treatment of children with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>In <z:e sem="disease" ids="C0935681" disease_type="Neoplastic Process" abbrv="">non-hematologic malignancies</z:e>, treatment for <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and <z:mpath ids='MPATH_310'>germ-cell tumors</z:mpath> has been associated with a 1-5% lifetime risk of both lymphoid as well as myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> cases the risk of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> drops sharply by 10 years after treatment </plain></SENT>
</text></document>